Education
About Us
Working with TipRanks
Follow Us
Phio Pharmaceuticals (PHIO)
:PHIO
PHIO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.97 - $9.79
Previous CloseN/A
Volume62.29K
Average Volume (3M)145.80K
Market Cap
$12.08M
Enterprise Value$492.91K
Total Cash (Recent Filing)$10.78M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.51
Next Earnings
Nov 06, 2025EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding5,726,750
10 Day Avg. Volume139,315
30 Day Avg. Volume145,799
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.04
Enterprise Value/Revenue7.04
Enterprise Value/Gross Profit-0.81
Enterprise Value/Ebitda-0.07
Forecast
1Y Price Target
$14.00Price Target Upside548.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Business DevelopmentPhio Pharmaceuticals maintains business development optionality as it advances its portfolio of conditionally active siRNA therapies.
Clinical TrialsThe PH-762 Phase 1b study continued to advance in the clinic, showing impressive efficacy in each cohort.
Safety ProfilePH-762 remains safe and well tolerated, with no dose-limiting toxicities, serious adverse events, or clinically meaningful treatment-emergent adverse reactions reported.
Bears Say
Financial RisksFactors that could impede reaching the price target include failed or inconclusive clinical trials and the inability to secure adequate funding.
Market CompetitionDespite the crowded skin cancer therapy market, there is a high unmet need due to the tumor's high incidence, less than optimal efficacy of available treatment options, and drug resistance to systemic therapies.
Phio Pharmaceuticals News
PHIO FAQ
What was Phio Pharmaceuticals’s price range in the past 12 months?
Phio Pharmaceuticals lowest stock price was $0.96 and its highest was $9.79 in the past 12 months.
What is Phio Pharmaceuticals’s market cap?
Phio Pharmaceuticals’s market cap is $12.08M.
When is Phio Pharmaceuticals’s upcoming earnings report date?
Phio Pharmaceuticals’s upcoming earnings report date is Nov 06, 2025 which is in 49 days.
How were Phio Pharmaceuticals’s earnings last quarter?
Phio Pharmaceuticals released its earnings results on Aug 14, 2025. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of -$0.36 by -$0.09.
Is Phio Pharmaceuticals overvalued?
According to Wall Street analysts Phio Pharmaceuticals’s price is currently Undervalued.
Does Phio Pharmaceuticals pay dividends?
Phio Pharmaceuticals does not currently pay dividends.
What is Phio Pharmaceuticals’s EPS estimate?
Phio Pharmaceuticals’s EPS estimate is -0.46.
How many shares outstanding does Phio Pharmaceuticals have?
Phio Pharmaceuticals has 5,726,750 shares outstanding.
What happened to Phio Pharmaceuticals’s price movement after its last earnings report?
Phio Pharmaceuticals reported an EPS of -$0.45 in its last earnings report, missing expectations of -$0.36. Following the earnings report the stock price went down -0.457%.
Which hedge fund is a major shareholder of Phio Pharmaceuticals?
Currently, no hedge funds are holding shares in PHIO
Company Description
Phio Pharmaceuticals
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
PHIO Stock 12 Month Forecast
Average Price Target
$14.00
▲(548.15% Upside)
Technical Analysis
Ibio
―
Evogene
―
Windtree Therapeutics
―
BioRestorative Therapies
―
Lixte Biotechnology Holdings
―
Ownership Overview
6.74% Insiders
2.31% Mutual Funds
0.25% Other Institutional Investors
90.09% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---